Carbapenemresistant; Escherichia coli; Klebsiella pneumoniae Background/Purpose: The emergence of carbapenem-resistant Enterobacteriaceae (CRE) is a cause for great concern. The aim of this study was to evaluate antimicrobial susceptibility, mechanisms of carbapenem-resistance in two members of the Enterobacteriaceae family (Escherichia coli and Klebsiella pneumoniae), and clinical outcomes of their infections. Methods: The susceptibility tests of 16 E. coli and 60 K. pneumoniae isolates, collected from 2010 to 2011, were assessed. The minimal inhibitory concentrations of eight antimicrobial agents were assessed by the broth microdilution method according to the recommendations of the Clinical and Laboratory Standards Institute. The detection of beta-lactamase genes was performed by polymerase chain reaction. The genetic relatedness of these isolates was determined by pulsed-field gel electrophoresis (PFGE) fingerprinting.
Introduction
The global spread of carbapenem-resistant Enterobacteriaceae (CRE) is an alarming crisis. According to the Study for Monitoring Antimicrobial Resistance Trends (SMART) program (2009e2010), the ertapenem resistance rate of Escherichia coli isolates from urinary tract infections was less than 2%. 1 However, the prevalence of CRE was as high as 31.6% in long-term acute-care facilities in south-east Michigan, USA. 2 This finding suggested that CRE is more prevalent in high-risk groups than in the healthy population.
Mechanisms of carbapenem resistance included carbapenemase production, a combination of AmpC hyperproduction and/or extended spectrum beta-lactamase (ESBL) production, and porin mutation 3 (such as ESBLs of SHV-and CTX-M types combined with a deficiency of OmpK35 or OmpK36 in Klebsiella pneumoniae, 4,5 AmpC overexpression and OmpC or OmpF in Enterobacter cloacae, 5 and CTX-M-type ESBL and loss of OmpC in E. coli 6 ). Various carbapenemases have been classified, including class A beta-lactamases (NMC, IMI, SME, KPC, GES), class B beta-lactamases (IMP, VIM, GIM, SPM, NDM), and class D beta-lactamase (OXA). 7 The carbapenemases KPC-2 8, 9 and NDM-1 9, 10 have been reported to have been spreading around the world since late 2000s. ST11 was reported to be the dominant clone of KPC-2-producing K. pneumoniae in China. 11 OXA-48-producing Enterobacteriaceae have been reported in Europe, East-Central Asia, and Africa. 9, 12 In Taiwan, the rate of ertapenem resistance in E. coli isolates increased from 0.1% in 1999 to 1.7% in 2007. 13 The rate of ertapenem resistance (shown by disk diffusion tests) among 2421 K. pneumoniae isolates from a Taiwanese hospital in 2008 was 13.5%. 14 Carbapenemases have been detected in Enterobacteriaceae in Taiwan, such as IMP-8 in K. pneumoniae 14 and E. cloacae, 15 VIM-2 in Citrobacter freundii, 15 and KPC-2 in K. pneumoniae. 16 However, OXA-producing Enterobacteriaceae have not yet been reported in Taiwan. The production of ESBL and/or AmpC combined with a loss of porins has been reported in Taiwan, for example the production of CMY-2 combined with a decreased expression of OmpF and/or OmpC in E. coli 13 ; and the loss of OmpK36 combined with a production of both ESBL and AmpC in K. pneumoniae 17 (such as CTX-M-14, SHV-12, and DHA-1; SHV-5 and DHA-1; SHV-12 and DHA-1; and CTX-M-14 and CMY-2). Few studies have investigated the prevalence rate of CRE, the types of carbapenemase, and the outcomes of CRE infections in Taiwan. We therefore conducted this study to evaluate these CRE-related issues.
Materials and methods

Bacterial strains
During the period January 2010 to December 2011, 8904 E. coli and 5820 K. pneumoniae isolates were identified at the Microbiology Laboratory of Taichung Veterans General Hospital (TCVGH). The disk diffusion test for Enterobacteriaceae was read according to the 2009 recommendations of the Clinical and Laboratory Standards Institute (CLSI). 18 In order to increase the possibility of identifying the carbapenemase, ertapenem-resistant Enterobacteriaceae with a positive confirmatory test for ESBL were not included in this study. Sixteen E. coli isolates and 60 K. pneumoniae isolates, which were resistant to ertapenem or intermediately resistant to ertapenem on disk diffusion tests and had negative confirmatory tests for ESBL using the double disk diffusion method, were collected for this study. The sources of 16 E. coli isolates included urine (25.0%), blood (12.5%), bile (6.3%), and others (including pus, discharge, ascites, and pleural effusion) (56.3%). The sources of 60 K. pneumoniae isolates included urine (21.7%), blood (18.3%), bile (18.3%), sputum (16.7%), and others (including pus, discharge, ascites, and pleural effusion) (25.0%).
Susceptibility test
The minimal inhibitory concentrations (MICs) of eight antimicrobial agents e aztreonam, amikacin, and cefepime (Bristol-Myers Squibb, NY, USA), imipenem (MSD, Rahway, NJ, USA), ceftazidime (GlaxoSmithKline, Greenford, UK), colistin (Sigma, St. Louis, MO, USA), ertapenem (MSD, Rahway, NJ, USA) and tigecycline (Wyeth, Monza, Italy) e were assessed using the broth microdilution method according to the CLSI's recommendations. 19 The MICs of colistin and tigecycline were interpreted according to the breakpoints recommended by the 2012 European Committee on Antimicrobial Susceptibility Testing (EUCAST), 20 while those of the other six antimicrobial agents were read according the breakpoints recommended by the 2012 CLSI guidelines. 21 All MIC tests were performed twice to avoid technical error. Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used as the quality control strains.
Modified Hodge test
The modified Hodge test (MHT; using ertapenem disks) was performed for all 76 isolates and interpreted according to the 2012 recommendations of the CLSI. 21 Positive and negative control testing of the MHT was performed using K. pneumoniae ATCC BAA-1705 and K. pneumoniae ATCC BAA-1706.
Molecular techniques
To carry out the polymerase chain reaction (PCR) to detect beta-lactamase genes, bacterial DNA extraction was performed using a QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). All isolates were screened for the resistance genes encoding KPC, GES, IMP-1, IMP-2, VIM-1, AmpC, SHV, CTX-M-Group 9 (CTX-M-G9), and OXA by PCR assay using previously described primers (Table 1) .
22e27 PCR products were sequenced for KPC-2, SHV-5, and CMY-2.
Pulsed-field gel electrophoresis (PFGE) was performed with a contour-clamped homogeneous electric field DRII apparatus from Bio-Rad Laboratories (Richmond, CA, USA) as previously described. 28 The chromosomal DNA was digested overnight with XbaI (Promega, Madison, WI, USA). DNA was electrophoresed in 1.2% SeaKem GTG agarose (FMC, Rockland, ME, USA) at 6 V/cm for 22 hours; the pulse time was increased from 2.2 to 54.2 seconds. The PFGE patterns were also analyzed using the computer software Gelcompar for Windows version 3.1b (Applied Math, Kortrijk, Belgium). The PFGE patterns were compared using the unweighted pair group method with arithmetic averages clustering method by using the Dice coefficient, according to the instructions of the Gelcompar manufacturer. A tolerance of 1.2% in the band position was applied during the comparison of PFGE fingerprinting patterns.
Multilocus sequence typing was carried out with seven housekeeping genes (rpoB, gapA, mdh, pgi, phoE, infB, and tonB) for K. pneumoniae. Allele sequences and sequence CTX-M-G9 (R) TTACAGCCCTTCGGCGATG types (STs) were identified at <http://www.pasteur.fr/ recherche/genopole/PF8/mlst/Kpneumoniae.html>. A different allele number was given to each distinct sequence within a locus, and a distinct ST number was assigned to each distinct combination of alleles.
Survival and bacteriologic assessments
The clinical outcomes of the 76 patients with acquired ertapenem-resistant Enterobacteriaceae isolates were analyzed by chart review. The clinical conditions (such as intensive care stay, ventilator use, previous stay in a nursing home, and prior antibiotic treatment) associated with the acquisition of ertapenem-resistant Enterobacteriaceae isolates were reviewed. The 30-day mortality rates among different groups of the 76 patients were analyzed by Yates' correction of continuity and Fisher's exact test, using the Statistical Package for the Social Science (version 15.1; SPSS Inc, Chicago, IL, USA). If the antibiotics (imipenem, meropenem, colistin, and tigecycline) were reported as active against these isolates and were administered to patients with ertapenem-resistant Enterobacteriaceae infection, these patients were classified into the observation group. None of the patients was treated with any combination of imipenem, colistin, or tigecycline. The mortality rates of patients treated with tigecycline, colistin, meropenem, and imipenem were also compared. Bacteriologic eradication was defined as a lack of growth of CRE from culture, or a lack of culture report due to removal of the drainage tube on the 14 th day of antibiotic treatment.
Results
The beta-lactamase genes detected in each ertapenemresistant E. coli and K. pneumoniae isolate are listed in Table 2 . Twenty-five isolates carried a single gene, including bla CMY-2 in 11 E. coli and 1 K. pneumoniae isolates, bla SHV-5 in 6 K. pneumoniae isolates, bla DHA in 6 K. pneumoniae isolates, and bla ACC in 1 E. coli isolate. The two-gene combination bla SHV-5 and bla DHA was found in 19 K. pneumoniae isolates. The combination of three genes, bla SHV-5 , bla DHA , and bla CTx-M-G9 , was found in 6 K. pneumoniae isolates. The class D beta-lactamase gene, bla OXA , was found in five K. pneumoniae isolates. Only one K. pneumoniae isolate was found to carry bla KPC-2 and was classified as ST11. A positive MHT result was found in 15 isolates (4 E. coli and 11 K. pneumoniae).
The most prevalent genes in ertapenem-resistant E. coli and K. pneumoniae isolates are listed in Table 3 . The bla CMY-2 gene (alone or in combination with other genes) was found in 93.8% of 16 E. coli isolates. The bla SHV-5 gene (alone or in combination) was found in 75.0% of 60 K. pneumoniae isolates. The bla DHA gene (alone or in combination with other genes) was found in 58.3% of 60 K. pneumoniae isolates. The combination bla SHV-5 ebla DHA (including further combination with other genes) was found in 45% of 60 K. pneumoniae isolates. The combination, Table 2 The beta-lactamase genes detected in each of the ertapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates Genes encoding beta-lactamases Escherichia coli (n) Klebsiella pneumoniae (n)
Positive modified Hodge test CMY-2  1  0  Total  16  60  15 bla SHV-5 ebla CTx-M-G9 (including further combination with other genes) was found in 26.7% of 60 K. pneumoniae isolates.
The antimicrobial susceptibilities of ertapenemresistant E. coli and K. pneumoniae isolates are listed in Table 4 . These 76 isolates showed moderate to high resistance to aztreonam, cefepime, and ceftazidime. All 16 E. coli isolates were susceptible to amikacin, but only 40% of the 60 K. pneumoniae isolates were susceptible to amikacin. Eight (50%) of 16 E. coli isolates were susceptible to imipenem. Fourteen (23.3%) of the 60 ertapenem-resistant K. pneumoniae were susceptible to imipenem. The susceptibility rates of 16 E. coli isolates to colistin and tigecycline were 62.5% and 75.0%, respectively. The susceptibility rates of 60 ertapenem-resistant K. pneumoniae to colistin and tigecycline were 58.3% and 50.0%, respectively.
The clinical conditions associated with the acquisition of ertapenem-resistant Enterobacteriaceae were treatment with antibiotics (93.4%), intensive care stay (60.5%), ventilator use (60.5%), and previous stay in a nursing home (26.3%). A comparison of 30-day mortality among the different groups of 76 patients who acquired ertapenemresistant Enterobacteriaceae is shown in Table 5 . The 30-day mortality rate of all the 76 patients was 40.8% (31/76). The 7-, 14-, 30-, and 90-day mortality rates of 33 patients in the observation group were 51.5%, 51.5%, 60.6%, 72.7%, respectively (p Z 0.247). There was no significant difference in the 30-day mortality rate between the 15 patients treated with tigecycline (73.3%) and the other 18 patients treated with colistin, imipenem, or meropenem (73.3% vs. 50.0%; p Z 0.313). Among 33 patients in the observation group, 20 patients had an abscess at the infection site. Among these 20 patients, 13 patients who underwent adequate drainage or surgical debridement had a higher survival rate than the other seven patients who did not (100% vs. 14.3%; p < 0.001). There was no significant difference in the 30-day mortality rate between the group with an imipenem MIC 1 mg/mL and the group with an imipenem MIC 4 mg/mL (40.9% vs. 35.0%; p Z 0.852). The bacteriologic eradication rates of tigecycline, imipenem, and colistin on the 14 th day of treatment were 66.7%, 50%, and 25%, respectively.
The
Discussion
The prevalence rates of ertapenem-resistant E. coli and K. pneumoniae isolated at TCVGH (tested by the disk diffusion method; CLSI 2009) 18 from 2010 to 2011 were 0.52% and 2.97%, respectively. The prevalence rates of CRE were lower than those of ESBL-producing Enterobacteriaceae. However, we were concerned that the major source of CRE isolates was the gastrointestinal tract. Colonization of CRE of the gastrointestinal tract could be observed for a median of 87 days (range 60e450 days). 29 CRE can spread from infected patients or hospital staff to families and communities by household or social contact, in contrast to the multidrug-resistant healthcare-associated, glucose-nonfermentive pathogens harbored mainly in the hospital environments. The example of ESBL-producing Enterobacteriaceae in the past 10 years indicates that CRE may rapidly reach a high rate worldwide 6 and result in a crisis of treatment failure.
The zone diameters of 12 isolates (5 E. coli and 7 K. pneumoniae) were interpreted as intermediately resistant to ertapenem by the microbiology laboratory at TCVGH according to breakpoints (susceptible, 19 mm; intermediately resistant, 16e18 mm; resistant, 15 mm) recommended by the CLSI (2009). 18 However, ertapenem MICs for all these 12 isolates were 1 mg/m (range 1e32 mg/mL) and were read as resistant according to breakpoints recommended by the CLSI (2012). 21 If the breakpoints of disk diffusion were updated according to the 2012 CLSI recommendations 21 (susceptible, 23 mm; intermediately resistant, 20e22 mm; resistant, 19 mm), the results of disk diffusion tests for these isolates would be read as resistant. Therefore, the susceptibility measurements would be consistent for the disk diffusion test and broth microdilution method. The ertapenem MICs for two additional isolates were 0.25 and 0.5 mg/mL, respectively, and were interpreted as susceptible according to breakpoints recommended by the CLSI (2012). 21 The beta-lactamase gene(s), MHT, and treatment outcomes for these two isolates were: CMY-2, positive MHT, treatment failure for the first one; and SHV-5, CTX-M-G9, and ACC, negative MHT, treatment failure for the second one.
Due to the complexity of the resistance mechanisms, CRE may exhibit a wide range of MICs for carbapenem, including some with only low levels of carbapenem resistance. 3 Intermediate susceptibility and even susceptibility to carbapenems have been observed for producers of all types of carbapenemase. 30 There is no consensus on the cut-off value of MICs of carbapenems that should be applied for research into carbapenemase activity. 30 The criteria for ertapenem resistance had not been clearly established by microbiologic (mechanisms and breakpoints) and clinical data, so these two isolates were included in this study.
The most prevalent genes were bla CMY-2 in 93.8% of 16 E. coli isolates, and bla SHV-5 in 75% of 60 K. pneumoniae isolates. Most isolates harbored combination genes, such as bla SHV-5 and bla DHA in 45% of 60 K. pneumoniae isolates, and bla SHV-5 and bla CTx-M-G9 in 26.7% of 60 K. pneumoniae isolates in this study. The bla genes associated with carbapenem resistance are complex. The bla genes of 16 bla KPC-2 -producing K. pneumoniae strains that have spread worldwide were analyzed. 8 These harbored a natural chromosome-encoded bla gene [bla SHV-1 ([12.5%), bla SHV-11 (68.7%), or bla OKP-A/B (18.8%)] and several acquired and plasmid-encoded genes [bla TEM-1 (81.3%), bla CTx-M-2 (31.3%), bla CTx-M-12 (12.5%), bla CTx-M-15 (18.7%), and bla OxA-9 (37.5%)]. The bla KPC-2 gene was always associated with one of the Tn4401 isoforms (a, b, or c). The complexity of betalactamase genes harbored in carbapenem-resistant isolates makes the phenotype-based identification of carbapenem resistance more difficult.
One K. pneumoniae isolate that carried the bla KPC-2 gene was classified as ST11. It was isolated from a patient who had been hospitalized in China. The dominant clone (ST11) of KPC-producing K. pneumoniae isolates was identified as originating from Zhejiang province (4 hospitals in Hangzhou d The difference in the 30-day mortality rates between the two groups, imipenem MIC 1 mg/mL and 4 mg/mL.
e The 30-day mortality rate of infections treated with each antibiotic of the observation group was compared with those treated by all the other antibiotics of the observation group. MIC Z minimal inhibitory concentration. Early identification of the KPC-producing K. pneumoniae isolates from patients linked epidemiologically with these endemic hospitals in Chinese cities is mandatory to control the spread.
Mechanisms of carbapenem resistance include carbapenemase production, 7e10 combination of AmpChyperproduction and/or extended spectrum betalactamase (ESBL)-production, and porin mutation. Enterobacteriaceae with ESBL production and porin mutation have been identified in Taiwan. 13, 17 According to the 74  59  61  67  21  57  22  52  72  64  29  31  62  63  44  37  20  23  55  12  69  73  78  5  3  11  7  71  49  32  25  28  6  17  18  35  38  68  24  26  1  9  77  47  33  39  50  54  42  34  10  43  66  65  27  56  15  19  36 33, 34 The sensitivity and specificity of the MHT for detecting carbapenemase were 77.4% and 38.9% in 54 carbapenemase and/or ESBL/AmpC-producing Enterobacteriaceae isolates, respectively, in one previous study. 33 False-positive MHT results could result from the production of ESBL or ampC. 33, 34 Five isolates were found to contain the bla OxA gene. Since OXA-48 was first detected in K. pneumoniae isolates in Turkey in 2003, OXA-48-producing Enterobacteriaceae have spread worldwide. 9, 12 Acinetobacter baumannii isolates with OXA-23, OXA-24, OXA-51, and OXA-58 have been reported in Taiwan. 35 However, Enterobacteriaceae with a bla OxA gene have never been reported in Taiwan. Therefore, sequencing of the bla OxA gene is needed to identify the types of bla OxA gene present.
PFGE-XbaI
The susceptibility rates of 60 ertapenem-resistant K. pneumoniae to colistin and tigecycline were 58.3% and 50.0%, respectively, in this study. The susceptibility patterns of CRE to colistin and tigecycline varied in different strains. 36 Susceptibility tests on 81 CRE isolates from the UK were performed using the agar dilution method recommended by the CLSI. 36 Chloramphenicol, ciprofloxacin, and nitrofurantoin inhibited less than 25% of isolates, whereas colistin was active against 75/81 isolates (92.6%), and tigecycline was active against 38/81 isolates (46.9%). 36 The MICs of ertapenem and imipenem against K. pneumoniae isolates showed a range from 0.5 to 256 mg/mL and 0.25 to 256 mg/mL, respectively, in this study. The range of carbapenem MIC for 49 CRE strains from China with different resistance mechanisms has been reported. 37 Moderate-to high-level carbapenem resistance in most isolates is more closely associated with a loss or decreased expression of both major porins combined with the production of AmpC or ESBL, while KPC-2, IMP-4, and IMP-8 carbapenemase production may lead to a low to moderate level of carbapenem resistance in Enterobacteriaceae in China. 37 There was no significant difference between the mortality rates of the group who acquired CRE susceptible to imipenem and those who acquired CRE resistant to imipenem (p Z 0.852). Patients in the observation group showed poor survival. In contrast, removal of the focus of infection (by debridement or drainage of the abscess) was associated with good survival. In a recent case-control study on the outcomes of carbapenem-resistant K. pneumoniae infection, removal of the focus of infection focus by an adjunctive procedure (i.e., debridement, drainage, or removal of the catheter) was associated with patient survival [odds ratio (OR) 0.14, 95% confidence interval (CI) 0.04e0.49; p Z 0.002]. 38 The administration of antibiotics with in vitro activity against carbapenem-resistant K. pneumoniae was not associated with patient survival (OR 2.3, 95% CI 0.73e7.24; p Z 0.15). 38 Although the patients treated with tigecycline had higher bacteriologic eradication rates, there was no significant difference in the 30-day mortality rate between these patients and the other patients in the observation group. The causes of mortality could be attributed to inadequate debridement or drainage, severity, and patient co-morbidity. If patients were stratified according to infection site, severity, and comorbidity, the number in each group would be too small to provide data of adequate sample size for the statistical analysis in this study. However, this study focused on the overview of clinical outcome rather than an analysis of risk factors for mortality.
The PFGE patterns of 60 K. pneumoniae isolates were relatively diverse, since some strains could have originated from different ancestors. This indicated that the Enterobacteriaceae could acquire a resistance gene from horizontal transfer of mobile genetic elements carrying a resistance gene (such as a plasmid or transposon). The fact that several clusters of ertapenem-resistant Enterobacteriaceae isolates were identified indicated that they had spread in the hospital via contacts. Appropriate strategies should be implemented to limit the spread of these pathogens, including active surveillance of patients with epidemiologic links to persons from whom CRE have been recovered, especially for high-risk groups (those with prior antibiotic treatment, an intensive care stay, ventilator use, or a previous stay in a nursing home). However, the costeffectiveness of active surveillance remains to be explored.
In conclusion, two carbapenemase genes, bla KPC-2 and bla OxA , were identified in carbapenem-resistant K. pneumoniae isolates. Other carbapenemase genes such as bla GES , bla IMP , and bla VIM were not detected. The genetic combinations bla SHV-5 ebla DHA and bla SHV-5 ebla CTx-M-G9 were prevalent in K. pneumoniae isolates. The mortality rates of patient-acquired ertapenem-resistant Enterobacteriaceae infection were high. Removal of the focus of infection (by debridement or drainage of the abscess) was associated with good survival. The findings of carbapenemase genes in a few isolates and small clusters of CRE indicated emerging problems at the hospital. Appropriate strategies should be implemented to control the spread of CRE.
